1. Department of Internal Medicine III, Ulm University, Ulm, Germany;
2. Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, and Department of Medicine V, University of Heidelberg, Heidelberg, Germany;
3. Department of Hematology Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, University of Pavia, Italy;
4. Second Department of Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany;
5. Cooperation Unit “Mechanisms of Leukemogenesis,” German Cancer Research Center, Heidelberg, Germany;
6. Department of Hematology, Medical University of Vienna, Vienna, Austria;
7. Roche Molecular Systems, Pleasanton, CA;
8. Pharmaceuticals Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland;
9. Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany;
10. Division of Molecular Genetics, German Cancer Research Center, Heidelberg, Germany;
11. Department I of Internal Medicine, Klinikum Schwabing, Munich, Germany; and
12. Institute for Medical Statistics and Epidemiology, Technical University Munich, Munich, Germany